P18.08.A CCNU/TMZ IN ELDERLY PATIENTS WITH MGMT-METHYLATED GLIOBLASTOMA: A MULTICENTRIC RETROSPECTIVE COHORT

Abstract BACKGROUND Lomustine-temozolomide combination therapy (CCNU/TMZ), in addition to standard radiotherapy, improves survival in MGMT-methylated newly diagnosed glioblastoma. As the CeTeG/NOA-09 trial included patients aged up to 70 years, the feasibility of CCNU/TMZ in older patients remains unknown. MATERIAL AND METHODS Retrospective multicentric analysis of patients aged >70 years with newly diagnosed MGMT-methylated glioblastoma, IDH-wildtype, receiving at least one dose of CCNU/TMZ according to the CeTeG/NOA-09 protocol. RESULTS Seventeen patients with a median age of 72 years (range, 71-78) were included. 71% (n=12) were male, the median KPS was 80% (IQR, 80-90), and the extent of resection was biopsy in 18% (n=3), partial resection in 24% (n=4), and gross total resection in 59% of cases (n=10). The median number of chemotherapy courses was five (IQR, 2-6). After a median follow-up of 19.1 months (IQR, 11.2-29.8), the median progression-free survival was 13.5 months (95%CI, 7.9-not reached) and the median overall survival was 20.7 months (95%CI, 17.6-not reached). Updated data will be presented at the meeting. CONCLUSION Combined radiochemotherapy with CCNU/TMZ is feasible in glioblastoma patients aged >70 years, and encouraging survival times were observed. Future prospective analyses involving CCNU/TMZ for MGMT-methylated glioblastoma might consider including elderly patients.